Sunesis Pharmaceuticals Inc., of South San Francisco, said it closed underwritten offerings of 10.99 million shares of its common stock, which included the exercise of the underwriter's overallotment option of 1.43 million shares, at 84 cents per share, and 20,200 shares of its nonvoting series B convertible preferred stock at $840 each. The company received combined gross proceeds of about $26.2 million from those offerings.